Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Reset all filters
01 7Aprovel
02 1Aprovel/CoAprovel
03 1Cozaar
04 5Cozaar/Hyzaar
05 3Diovan
06 11Diovan Group
07 2Diovan/Co-Diovan
08 2Entresto
09 1Exforge
10 4Exforge Group
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 735
2018 Revenue in Millions : 711
Growth (%) : 3
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 670
2019 Revenue in Millions : 815
Growth (%) : -18
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 461
2020 Revenue in Millions : 604
Growth (%) : -24
Irbesartan, Irbesartan+Hydrochlorothiazide
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : -17.60%
2013 Revenue in Millions :
Growth (%) :
Irbesartan, Irbesartan+Hydrochlorothiazide
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 800
2014 Revenue in Millions : 838
Growth (%) : 5%
Irbesartan, Irbesartan+Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 722
2015 Revenue in Millions : 808
Growth (%) : -11
Irbesartan, Irbesartan + Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 857
2016 Revenue in Millions : 844
Growth (%) : 1
Irbesartan, Irbesartan + Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 737
2017 Revenue in Millions : 781
Growth (%) : -6%
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 2,497
2019 Revenue in Millions : 1,726
Growth (%) : 45
Hydrochlorothiazide, Valsartan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,003
2019 Revenue in Millions : 1,064
Growth (%) : -6